Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Mar 26;179(12):1107–1114. doi: 10.1164/rccm.200810-1584OC

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2009, American Thoracic Society

PMC Copyright notice

Figure 5. — Simvastatin inhibits lipopolysaccharide (LPS)-induced matrix metalloproteinase (MMP) concentration. Healthy human volunteers inhaled 50 μg LPS. Simvastatin or placebo was administered for 4 days before LPS inhalation. Bronchoaveolar lavage fluid (BALF) was obtained 6 hours after inhalation of LPS and supernatants were analyzed for (A) MMP-7, (B) MMP-8, and (C) MMP-9. Data are shown for the 10 subjects in the placebo group and the 20 subjects in the combined simvastatin group. Open bars = placebo; solid bars = simvastatin. Data for MMP-7 are medians (interquartile range). *P < 0.05 versus placebo.

Figure 5. — Simvastatin inhibits lipopolysaccharide (LPS)-induced matrix metalloproteinase (MMP) concentration. Healthy human volunteers inhaled 50 μg LPS. Simvastatin or placebo was administered for 4 days before LPS inhalation. Bronchoaveolar lavage fluid (BALF) was obtained 6 hours after inhalation of LPS and supernatants were analyzed for (A) MMP-7, (B) MMP-8, and (C) MMP-9. Data are shown for the 10 subjects in the placebo group and the 20 subjects in the combined simvastatin group. Open bars = placebo; solid bars = simvastatin. Data for MMP-7 are medians (interquartile range). *P < 0.05 versus placebo.